Clinical Trials Browser

Glioblastoma, Neoplasms

NCT04901702 2026-02-09

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT05421897 2026-01-29

RAPID

Phase 1 Active not recruiting

11 enrolled

CNS

Neoplasms, Neuroblastoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Phase 1/2 Recruiting

90 enrolled

CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1 Terminated

40 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT03213002 2025-04-09

CAPTEM

Phase 1/2 Recruiting

67 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms

NCT03709680 2025-01-14

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 2 Active not recruiting

128 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Bone Neoplasms, Medulloblastoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdoid Tumor

NCT06012695 2024-11-14

NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma

Phase 1/2 Recruiting

79 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT04525014 2024-10-31

PIRATE

Phase 1 Terminated

2 enrolled

CNS

Brain Neoplasms, Neoplasms, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT00582075 2023-03-27

RAD0102

Phase 2 Completed

25 enrolled 8 charts

CNS

Brain Neoplasms, Neoplasms

NCT01528046 2023-01-13

Metformin in Children With Relapsed or Refractory Solid Tumors

Phase 1 Completed

26 enrolled

CNS

Brain Neoplasms, Neoplasms, Recurrence

NCT02507232 2020-07-28

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

Phase EARLY_PHASE1 Terminated

2 enrolled

CNS

Glioma, Neoplasms

NCT04388033 2020-06-09

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Phase 1/2 Unknown

10 enrolled

CNS

Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Neoplasms, Neuroepithelial

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1 Terminated

4 enrolled 8 charts

CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

NCT01480479 2018-01-16

ACT IV

Phase 3 Completed

745 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2 Completed

141 enrolled

CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

Clinical Trials

BRIDGES

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RAPID

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

9-ING-41 in Pediatric Patients With Refractory Malignancies.

CAPTEM

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma

PIRATE

RAD0102

Metformin in Children With Relapsed or Refractory Solid Tumors

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

ACT IV

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma